Abbvie Inc ABBV Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$285.42 up $2.02, 0.71% at close Oct 16
Last close · Previous close $283.40
- Market cap
- At the Oct 16 close
- P/E ratio
- 80.63On last 12 months’ EPS
- Diluted EPS
- $3.54Last 12 months
- Dividend yield
- 2.42%Last 12 months
Price chart
$285.42up $2.02, 0.71%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$283.40Oct 15
- Volume5.64MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume5.01MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $190.75 to $291.40; now $285.42
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ABBV beat the S&P 500 in all 7 periods.
| Period | ABBV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ABBV: up 9.4% S&P 500: up 1.5% | ABBV beat the S&P 500 by 7.9 percentage points Beat |
| 3M | ABBV: up 12.9% S&P 500: up 1.9% | ABBV beat the S&P 500 by 11.0 percentage points Beat |
| YTD | ABBV: up 28.6% S&P 500: up 12.8% | ABBV beat the S&P 500 by 15.8 percentage points Beat |
| 1Y | ABBV: up 29.6% S&P 500: up 16.8% | ABBV beat the S&P 500 by 12.8 percentage points Beat |
| Long term | ||
| 3Y | ABBV: up 114.3% S&P 500: up 81.5% +28.9% vs +22.0% a year | ABBV beat the S&P 500 by 32.8 percentage points Beat |
| 5Y | ABBV: up 212.1% S&P 500: up 83.1% +25.6% vs +12.9% a year | ABBV beat the S&P 500 by 129.0 percentage points Beat |
| 10Y | ABBV: up 613.1% S&P 500: up 319.6% +21.7% vs +15.4% a year | ABBV beat the S&P 500 by 293.5 percentage points Beat |
$10,000 invested in ABBV 10 years ago (Oct 14, 2016) would be worth about $71,314 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
ABBV beat the S&P 500 in all 7 periods.
| Period | ABBV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ABBV: up 8.7% S&P 500: up 1.2% | ABBV beat the S&P 500 by 7.5 percentage points Beat |
| 3M | ABBV: up 12.2% S&P 500: up 1.7% | ABBV beat the S&P 500 by 10.5 percentage points Beat |
| YTD | ABBV: up 24.9% S&P 500: up 11.9% | ABBV beat the S&P 500 by 13.0 percentage points Beat |
| 1Y | ABBV: up 25.8% S&P 500: up 15.5% | ABBV beat the S&P 500 by 10.3 percentage points Beat |
| Long term | ||
| 3Y | ABBV: up 93.9% S&P 500: up 75.0% +24.7% vs +20.5% a year | ABBV beat the S&P 500 by 18.9 percentage points Beat |
| 5Y | ABBV: up 161.1% S&P 500: up 71.2% +21.2% vs +11.4% a year | ABBV beat the S&P 500 by 89.9 percentage points Beat |
| 10Y | ABBV: up 374.4% S&P 500: up 258.1% +16.8% vs +13.6% a year | ABBV beat the S&P 500 by 116.3 percentage points Beat |
$10,000 invested in ABBV 10 years ago (Oct 14, 2016) would be worth about $47,436 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$285.42
Closing high on .
Split-adjusted daily closes since Jan 2, 2013.
Stock splits
ABBV hasn’t split since its price history begins in 2013.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $64.39Bup 10.4%
- Net income
- $6.31Bup 67.7%
- Diluted EPS
- $3.54up 68.6%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $14.46B | $1.56B | $0.88 |
| Q4 FY24 (Dec 31, 2024) | $15.10B | −$22.00M | −$0.02 |
| Q1 FY25 (Mar 31, 2025) | $13.34B | $1.29B | $0.72 |
| Q2 FY25 (Jun 30, 2025) | $15.42B | $938.00M | $0.52 |
| Q3 FY25 (Sep 30, 2025) | $15.78B | $186.00M | $0.10 |
| Q4 FY25 (Dec 31, 2025) | $16.62B | $1.82B | $1.02 |
| Q1 FY26 (Mar 31, 2026) | $15.00B | $695.00M | $0.39 |
| Q2 FY26 (Jun 30, 2026) | $16.99B | $3.61B | $2.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $56.20B | $11.54B | $6.45 |
| FY22 (Dec 31, 2022) | $58.05B | $11.84B | $6.63 |
| FY23 (Dec 31, 2023) | $54.32B | $4.86B | $2.72 |
| FY24 (Dec 31, 2024) | $56.33B | $4.28B | $2.39 |
| FY25 (Dec 31, 2025) | $61.16B | $4.23B | $2.36 |
Margins
- Gross 71.5%
- Operating 26.2%
- Net 9.8%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $18.21BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$19.51BLast 12 months
- Capital spending$1.30BLast 12 months
- 28.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.39BLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$11.98BLast 12 months
- Total returned$13.37BLast 12 months
73% of free cash flow
Balance sheet
- $6.84BAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$70.82BAs of Jun 30, 2026
- Net debt$63.99BAs of Jun 30, 2026
- 0.81As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 4.7%Last 12 months
Over the last 12 months, Abbvie’s net income was 4.7% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $2.28 |
| 2017 | $2.56 |
| 2018 | $3.59 |
| 2019 | $4.28 |
| 2020 | $4.72 |
| 2021 | $5.20 |
| 2022 | $5.64 |
| 2023 | $5.92 |
| 2024 | $6.20 |
| 2025 | $6.56 |
| 2026 (to date) | $6.92 |
Dividend details
- $6.92Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield2.42%Last 12 months
- $1.73Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- up 6.8% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 12 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 195.5%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Abbvie Inc
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease. Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Illinois, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
ABBV news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ABBV stock FAQ
What is ABBV stock’s price today?
Abbvie (ABBV) traded at $285.42 at the close on , up $2.02 (0.71%) from the previous close of $283.40. Over the past 52 weeks it has traded between $190.75 and $291.40.
If you invested $1,000 in ABBV 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ABBV on would be worth about $7,131 at the close on , a total return of +613.1%. The same $1,000 would be worth $3,121 if invested five years ago and $1,296 if invested one year ago. Past performance doesn’t predict future returns.
What is ABBV’s P/E ratio?
ABBV trades at 80.6 times its diluted earnings over the four quarters to ($3.54 per share), at the close. (How the P/E ratio works.)
How much revenue does Abbvie make?
Abbvie reported $64.4 billion of revenue over the four quarters to , up 10.4% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $17.0 billion, up 10.2% from a year earlier.
Is Abbvie profitable?
Yes. Abbvie earned $6.3 billion of net income over the four quarters to , a net margin of 9.8%, and its operating margin was 26.2% (what margins tell you).
What are ABBV’s earnings per share?
ABBV’s diluted earnings per share were $3.54 over the four quarters to , compared with $2.10 in the twelve months before. The latest quarter (Q2 FY26) brought $2.03 per share, against $0.52 a year earlier (how EPS works).
Does ABBV pay a dividend?
Yes. Abbvie pays a quarterly dividend. The most recent was $1.73 per share, with an ex-dividend date of . Over the last twelve months it paid $6.92 per share, a 2.42% yield at the close, and the full-year dividend has risen 12 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($6.92 per share), and if the next 12 months match the last 12, 100 shares would receive about $692 over 12 months, and $1,000 over 12 months would take about 145 shares, roughly $41,386 at the close. Dividends can change.
What is ABBV’s 52-week high and low?
Over the past 52 weeks ABBV has traded as low as $190.75 and as high as $291.40. At $285.42 at the close on , it is 2.1% below that high and 49.6% above the low.
What is ABBV’s all-time high?
ABBV’s highest closing price was $285.42 on , adjusted for stock splits.
Has ABBV stock ever split?
No. ABBV hasn’t split since its price history begins in 2013.
How has ABBV stock performed?
Including dividends and measured to the close on , ABBV has returned +28.6% so far this year and +29.6% over the past year, and +212.1% over five years (+25.6% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Abbvie in?
Abbvie is in the Healthcare sector and the Drug Manufacturers - General industry, and is headquartered in Illinois, USA.
What exchange does ABBV trade on?
Abbvie trades on the NYSE under the ticker symbol ABBV. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.